Top Story, SYN, Startups, Daily

Digital health startup Better is calling it quits

Backed by Social + Capital Partnership and Mayo Clinic, the company provided subscribers a review of their insurance and medical bills by a personal health assistant to cut through medical jargon and resolve problems.

Healthcare startup Better, a Palo-Alto based company co-founded by Geoffrey Clapp in 2013, has shut down.

The company provided free tools and access to a team of personal health assistants to help users improve their health. Through a combination of automation and live access to nurses, subscribers would receive a review of their insurance designed to cut through industry jargon and help in resolving problems with medical bills or insurance. Its investors included the Mayo Clinic’s investment arm and the Social+Capital Partnership.

Single memberships cost about $20 and family memberships cost $50.

The company stated on its website and in a series of tweets that it would shut down October 30. Clapp did not immediately return calls requesting additional comment.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

The news was received by members and supporters with sadness and disappointment.


https://twitter.com/richarddjordan/status/648949849195352064

Prior to Better, Clapp had been the CTO and COO for Health Hero Network, a telemedicine business that has worked with the Department of Veterans Affairs and McKesson.

Better’s imminent shutdown underscores the precariousness of startups in the healthcare sector if they can’t strike a balance between a product end users are willing to pay for and that the healthcare industry is willing to support.